[1]王斌,王艳杰,梁贵文,等.乳积方防治乳腺癌患者术后复发转移的临床研究*[J].西部中医药,2013,26(08):101-104.
　WANG Bin,WANG Yanjie,LIANG Guiwen,et al.Clinical Study on RuJiFang to Prevent Postoperative Recurrence and Metastasis of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(08):101-104.
点击复制

乳积方防治乳腺癌患者术后复发转移的临床研究*
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
26
期数:
2013年08期
页码:
101-104
栏目:
出版日期:
2013-08-15

文章信息/Info

Title:
Clinical Study on RuJiFang to Prevent Postoperative Recurrence and Metastasis of Breast Cancer
文章编号:
1004-6852(2013)08-0101-04
作者:
王斌，王艳杰，梁贵文，黄小青，陈学彰，杨耀林，李宏良，黄泳立，田华琴△
佛山市中医院，广东 佛山 528000
Author(s):
WANG Bin, WANG Yanjie, LIANG Guiwen, HUANG Xiaoqing, CHEN Xuezhang, YANG Yaolin, LI Hongliang, HUANG Yongli, TIAN Huaqin△
Foshan Hospital of TCM, Foshan 528000, China
关键词:
乳腺癌; 乳积方; 总生存; 无病生存; 生存质量
Keywords:
breast cancer;  RuJiFang;  overall survival (OS);  disease-free survival (DFS);  life quality
分类号:
R684
文献标志码:
B
摘要:
目的：观察自拟乳积方防治乳腺癌患者术后复发转移的临床疗效。方法：回顾性分析109例手术后的乳腺癌患者，根据服药情况分为治疗组(乳积方配合西药组)57例和对照组(西药组)52例，观察患者的总生存率(OS)、无疾病生存率(DFS)、生存质量情况。结果：2组患者在年龄、月经状况、病理类型、临床分期、淋巴结转移情况、激素受体表达情况、Her-2表达情况等基线资料方面，具备方差齐性，差异无统计学意义(P＜0.05)。随访时间13～126月，中位随访时间61月；2组3年DFS率分别为91.4%和68.4%，差异有统计学意义(P＜0.01)；3年OS率分别为100.0%和97.1%，差异无统计学意义(P＞0.05)；5年DFS率分别为63.6%和36.8%，差异有统计学意义(P＜0.01)。5年OS率分别为93.5%和62.5%，差异有统计学意义(P＜0.01)；采用乳腺癌患者生存质量评分系统(FACT-B)对患者生存质量进行评分，治疗组治疗后各项功能较治疗前有明显改善，差异有统计学意义(P＜0.01)；对照组部分功能较治疗前有明显改善，差异有统计学意义(P＜0.01)；治疗后2组各项功能评分比较，差异有统计学意义(P＜0.01)。结论：乳积方配合西药治疗乳腺癌术后患者，可进一步延长患者总生存及无疾病生存时间，改善患者生存质量。
Abstract:
Objective: To verify therapeutic effects of self-design RuJiFang in preventing postoperative recurrence and metastasis of patients with breast cancer. Method: The conditions of 109 patients were retrospectively analyzed, and the patients were divided to 57 cases of the treatment group(RuJiFang and western medicine) and 52 cases of the control group(western medicine) according to the medication. Overall survival(OS) rates, disease-free survival(DFS) rates and life qualities of the patients were observed. Result: There was homogeneity of variance existed in the age, menstrual state, pathological types, the phases, lymph nodes, hormone receptor, Her-2 expression and others for the patients of both groups, the difference had no statistical meaning(P＜0.05). The follow-up visiting were 13 to 126 months, median follow-ups were 61 months. DFS rates of both groups in three years were respectively 91.4% and 68.4%, the difference had statistical meaning(P＜0.01). OS rates in three years were respectively 100.0% and 97.1%, the difference had no statistical meaning (P＞0.05); DFS rates of both groups in five years were 63.6% and 36.8%, the difference had statistical meaning(P＜0.01). OS rates in five years were 93.5% and 62.5%, the difference had statistical meaning (P＜0.01). Life quality of the patients was evaluated with functional assessment of cancer therapy for breast cancer(FACT-B), the scores were improved after treating than before in the treatment group, the difference had statistical meaning(P＜0.01); part of the functions in the control group were improved remarkably than before, the difference had statistical meaning(P＜0.01); the differences had statistical meaning between both groups in function scores after treating (P＜0.01). Conclusion: RuJiFang and western medicine for postoperative patients with breast cancer could improve life quality of the patients and prolong OS time and DFS time.

相似文献/References:

[1]侯俊明,江静.疏肝解郁法联合化疗治疗乳腺癌临床疗效分析[J].西部中医药,2014,27(09):1.
[2]王丽,何丽娟,朱玉芹.循证护理对乳腺癌化疗患者自尊水平和应对方式的影响[J].西部中医药,2014,27(11):134.
[3]朱慧华.纽曼护理对乳腺癌手术患者心理健康和生活质量的影响[J].西部中医药,2014,27(12):105.
[4]张晓华,张晓岚△,梁玉荣,等.综合心理干预对乳腺癌化疗患者医学应对方式及生命质量的影响[J].西部中医药,2015,28(07):123.
[5]谷雨,华海清△.中医辨证分型与乳腺癌预后的相关性研究[J].西部中医药,2015,28(04):85.
[6]刘琛,吴黎雅,赵红佳,等.人参养荣汤干预乳腺癌新辅助化疗所致气血两虚证的临床研究[J].西部中医药,2011,24(11):3.
[7]李树建.扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究[J].西部中医药,2013,26(09):1.
　LI Shujian.Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(08):1.
[8]安妮,杨俊兰.消 疒徵祛积方联合化疗对晚期乳腺癌患者血清CEA、CA125、CA153和CA19-9含量及临床疗效的影响[J].西部中医药,2013,26(03):7.
　AN Ni,YANG Junlan.Effects of XiaoZhen QuJiFang and Chemotherapy on Clinical Efficacy and Contents of Serum CEA, CA125, CA153 and CA19-9 of Patients with Mammary Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(08):7.
[9]朱竹华,许敏菊,张汀荣,等.以家庭为中心的护理模式在完全植入式静脉输液港乳腺癌化疗患者中的应用[J].西部中医药,2016,29(03):114.
　ZHU Zhuhua,XU Minju,ZHANG Dingrong,et al.FCC Applying to Breast Cancer Patients Who Received Chemotherapy by TIVAP[J].Western Journal of Traditional Chinese Medicine,2016,29(08):114.
[10]王泽芬.集束护理干预策略对乳腺癌保乳术后放化疗患者的影响[J].西部中医药,2015,28(04):137.

备注/Memo

备注/Memo:
收稿日期：2013-01-05 *基金项目：广东省中医药局科研项目(编号2010002) 作者简介：王斌(1979—)，男，主治医师。研究方向：乳腺癌、肺癌、癌痛的中西医治疗。 △通讯作者：田华琴(1963—)，女，主任医师，教授，硕士研究生导师。研究方向：乳腺癌、肝癌的中西医治疗。
更新日期/Last Update: 2013-08-15